➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Baxter
Dow
McKinsey
Boehringer Ingelheim

Last Updated: August 3, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,980,853


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,980,853 protect, and when does it expire?

Patent 8,980,853 protects SPINRAZA and is included in one NDA.

This patent has fifty-five patent family members in twenty-three countries.

Summary for Patent: 8,980,853
Title:Compositions and methods for modulation of SMN2 splicing in a subject
Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
Inventor(s): Bennett; C. Frank (Carlsbad, CA), Hung; Gene (San Diego, CA), Rigo; Frank (Carlsbad, CA), Krainer; Adrian R. (Huntington Square, NY), Hua; Yimin (Jericho, NY), Passini; Marco A. (Shrewsbury, MA), Shihabuddin; Lamya (Brighton, MA), Cheng; Seng H. (Natick, MA), Klinger; Katherine W. (Sudbury, MA)
Assignee: Isis Pharmaceuticals, Inc. (Carlsbad, CA) Cold Spring Harbor Laboratory (Cold Spring Harbor, NY)
Application Number:13/380,021
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,980,853

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biogen Idec SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,980,853

PCT Information
PCT FiledJune 17, 2010PCT Application Number:PCT/US2010/039077
PCT Publication Date:December 23, 2010PCT Publication Number: WO2010/148249

International Family Members for US Patent 8,980,853

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010262862 ⤷  Try it Free
Australia 2016200344 ⤷  Try it Free
Canada 2765396 ⤷  Try it Free
China 102665731 ⤷  Try it Free
China 106983768 ⤷  Try it Free
Cyprus 1120807 ⤷  Try it Free
Denmark 3305302 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Harvard Business School
McKinsey
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.